The Filing Desk

CG Oncology vs CRISPR Therapeutics

CG Oncology CGON · CRISPR Therapeutics CRSP · Biotechnology

CG Oncology reported revenue of $4 million in fiscal 2025, about the same as CRISPR Therapeutics' $4 million in fiscal 2025. CG Oncology's revenue grew 254.7% in its latest year, and CRISPR Therapeutics' fell 90.6%. CG Oncology had an operating margin of -4722.1%, against -18933.7% at CRISPR Therapeutics. Free cash flow was −$132 million at CG Oncology and −$346 million at CRISPR Therapeutics.

Side by side

CG OncologyCRISPR Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$4M
Revenue growth254.7%−90.6%
Revenue growth a year, last 5 years—38.0%
Gross margin——
Operating margin−4,722.1%−18,933.7%
Net margin−3,985.0%−16,569.8%
Free cash flow−$132M−$346M
Free cash flow margin−3,279.2%−9,855.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.7%6.6%
Last close$74.40$42.24
P/E at the last close——
Insider trades, last 12 monthsbought $24.8 million, sold $4.8 millionsold $14.5 million
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CG OncologyCRISPR Therapeutics
Operating margin
Percent of revenue
CG OncologyCRISPR Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CG OncologyCRISPR Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CG Oncology and CRISPR Therapeutics pages.